Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Debt (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Total Debt data on record, last reported at $109.1 million in Q3 2025.

  • For Q3 2025, Total Debt rose 4.49% year-over-year to $109.1 million; the TTM value through Sep 2025 reached $109.1 million, up 4.49%, while the annual FY2024 figure was $102.5 million, 1.9% up from the prior year.
  • Total Debt reached $109.1 million in Q3 2025 per BTAI's latest filing, roughly flat from $108.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $109.1 million in Q3 2025 and bottomed at $56000.0 in Q1 2022.
  • Average Total Debt over 4 years is $91.7 million, with a median of $100.6 million recorded in 2023.
  • Peak YoY movement for Total Debt: surged 170332.14% in 2023, then grew 1.9% in 2024.
  • A 4-year view of Total Debt shows it stood at $93.5 million in 2022, then grew by 7.62% to $100.6 million in 2023, then increased by 1.9% to $102.5 million in 2024, then grew by 6.46% to $109.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $109.1 million in Q3 2025, $108.7 million in Q2 2025, and $105.5 million in Q1 2025.